Skip to content

Study · Not a test of the peptide alone · 2025

3 results

Cost-effectiveness of Cerebrolysin as an add-on treatment for neurorecovery after traumatic brain injury.

Strilciuc S, Grad DA, Vlădescu C, Buzoianu AD, Albu C, Mureșanu DF

Journal of medicine and life1 Apr 2025

PMID40405935 (opens in a new tab)PMCIDPMC12094318 (opens in a new tab)DOI10.25122/jml-2025-0087 (opens in a new tab)PepBankPUB-40405935
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Traumatic brain injuries (TBIs) are a leading cause of death and long-term disability worldwide, with incidence and injury mechanisms varying by age group and region. Impairment of functional status, diagnoses of anxiety and depression are encountered post-TBI. Studies have shown that Cerebrolysin can have positive effects among TBI survivors. We conducted a cost-effectiveness analysis (CEA) among patients with moderate TBI, using data from the CAPTAIN II trial. This exercise was carried out on a three-month timeline from the provider's perspective. Two models were incorporated in the CEA: control (placebo group) and treatment (Cerebrolysin group). Our analysis showed that Cerebrolysin had a high probability of being cost-effective, based on Glasgow Outcome Scale Extended (GOSE) (in over 80% of patients with moderate TBI), Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety scores (for the former two, in over 95% of patients with moderate TBI), when assuming a lasting effect (12 months) of the CAPTAIN trial intervention protocol. A model-based approach is needed to account for potential sources of bias beyond the 90-day observation period of this clinical trial. Furthermore, economic evaluations incorporating patients diagnosed with all TBI severities are needed.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01Computer modelNot a test of Cerebrolysin aloneIn silicoOther

    In a moderate TBI economic model, Cerebrolysin had high GOSE-based cost-effectiveness probability when a lasting effect of 12 months was assumed.

    In plain wordsIn a moderate TBI model, Cerebrolysin had high GOSE-based cost-effectiveness probability versus placebo, assuming effects lasted 12 months.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableGOSE-based cost-effectiveness probability
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Our analysis showed that Cerebrolysin had a high probability of being cost-effective, based on Glasgow Outcome Scale Extended (GOSE) (in over 80% of patients with moderate TBI),
    4 context sentences
    Summary · context
    when assuming a lasting effect (12 months) of the CAPTAIN trial intervention protocol.
    Summary · context
    We conducted a cost-effectiveness analysis (CEA) among patients with moderate TBI, using data from the CAPTAIN II trial.
    Summary · context
    This exercise was carried out on a three-month timeline from the provider's perspective.
    Summary · context
    Two models were incorporated in the CEA: control (placebo group) and treatment (Cerebrolysin group).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02Computer modelNot a test of Cerebrolysin aloneIn silicoOther

    In a moderate TBI economic model, Cerebrolysin had high depression-based cost-effectiveness probability when a lasting effect of 12 months was assumed.

    In plain wordsIn a moderate TBI model, Cerebrolysin had high depression-based cost-effectiveness probability versus placebo, assuming effects lasted 12 months.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableHADS depression-based cost-effectiveness probability
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety scores (for the former two, in over 95% of patients with moderate TBI),
    4 context sentences
    Summary · context
    when assuming a lasting effect (12 months) of the CAPTAIN trial intervention protocol.
    Summary · context
    We conducted a cost-effectiveness analysis (CEA) among patients with moderate TBI, using data from the CAPTAIN II trial.
    Summary · context
    This exercise was carried out on a three-month timeline from the provider's perspective.
    Summary · context
    Two models were incorporated in the CEA: control (placebo group) and treatment (Cerebrolysin group).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  3. 03Computer modelNot a test of Cerebrolysin aloneIn silicoOther

    In a moderate TBI economic model, Cerebrolysin had high anxiety-based cost-effectiveness probability when a lasting effect of 12 months was assumed.

    In plain wordsIn a moderate TBI model, Cerebrolysin had high anxiety-based cost-effectiveness probability versus placebo, assuming effects lasted 12 months.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableHADS anxiety-based cost-effectiveness probability
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cost-effectiveness · Pharmacology

    Source sentences

    Summary
    Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety scores (for the former two, in over 95% of patients with moderate TBI),
    4 context sentences
    Summary · context
    when assuming a lasting effect (12 months) of the CAPTAIN trial intervention protocol.
    Summary · context
    We conducted a cost-effectiveness analysis (CEA) among patients with moderate TBI, using data from the CAPTAIN II trial.
    Summary · context
    This exercise was carried out on a three-month timeline from the provider's perspective.
    Summary · context
    Two models were incorporated in the CEA: control (placebo group) and treatment (Cerebrolysin group).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.